Related references
Note: Only part of the references are listed.Orthogonal Halogen-Bonding-Driven 3D Supramolecular Assembly of Right-Handed Synthetic Helical Peptides
Peng Teng et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2019)
Inhibition of β-catenin/B cell lymphoma 9 protein-protein interaction using α-helix-mimicking sulfono-γ-AApeptide inhibitors
Peng Sang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Cyclic Peptidomimetics as Inhibitor for miR-155 Biogenesis
Hao Yan et al.
MOLECULAR PHARMACEUTICS (2019)
Stabilization of lncRNA GAS5 by a Small Molecule and Its Implications in Diabetic Adipocytes
Yan Shi et al.
CELL CHEMICAL BIOLOGY (2019)
De Novo Left-Handed Synthetic Peptidomimetic Foldamers
Fengyu She et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2018)
Hydrogen-Bonding-Driven 3D Supramolecular Assembly of Peptidomimetic Zipper
Peng Teng et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2018)
Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
Alexey A. Larionov
FRONTIERS IN ONCOLOGY (2018)
One-Bead Two-Compound Thioether Bridged Macrocyclic γ-AApeptide Screening Library against EphA2
Yan Shi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Right-Handed Helical Foldamers Consisting of De Novo D-AApeptides
Peng Teng et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2017)
Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and metaanalysis of randomised controlled trials
Zhi-Qiao Xu et al.
BMJ OPEN (2017)
Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature
Fausto Petrelli et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
γ-AApeptides: Design, Structure, and Applications
Yan Shi et al.
ACCOUNTS OF CHEMICAL RESEARCH (2016)
γ-AApeptides as a New Class of Peptidomimetics
Peng Teng et al.
CHEMISTRY-A EUROPEAN JOURNAL (2016)
Targeting Stereotyped B Cell Receptors from Chronic Lymphocytic Leukemia Patients with Synthetic Antigen Surrogates
Mohosin Sarkar et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness
Arlene Chan
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2016)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Carlos L. Arteaga et al.
CANCER CELL (2014)
Recognition of Antigen-Specific B-Cell Receptors from Chronic Lymphocytic Leukemia Patients by Synthetic Antigen Surrogates
Mohosin Sarkar et al.
CHEMISTRY & BIOLOGY (2014)
Pertuzumab: new hope for patients with HER2-positive breast cancer
M. Capelan et al.
ANNALS OF ONCOLOGY (2013)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The ERBB network: at last, cancer therapy meets systems biology
Yosef Yarden et al.
NATURE REVIEWS CANCER (2012)
Resistance to HER2-directed antibodies and tyrosine kinase inhibitors
Joan T. Garrett et al.
CANCER BIOLOGY & THERAPY (2011)
Choosing the right cell line for breast cancer research
Deborah L. Holliday et al.
BREAST CANCER RESEARCH (2011)
Development of antibody surrogates for the treatment of cancers and autoimmune disease
Thomas Kodadek
CURRENT OPINION IN CHEMICAL BIOLOGY (2010)
Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
Werner Scheuer et al.
CANCER RESEARCH (2009)
A peptoid Antibody surrogate that antagonizes VEGF receptor 2 activity
D. Gomika Udugamasooriya et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2008)
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB Ligands and remain dependent on the ErbB receptor network
Christoph A. Ritter et al.
CLINICAL CANCER RESEARCH (2007)
Synthesis and evaluation of bivalent NDP-α-MSH(7) peptide ligands for binding to the human melanocortin receptor 4 (hMC4R)
Heather L. Handl et al.
BIOCONJUGATE CHEMISTRY (2007)
Lapatinib: Current status and future directions in breast cancer
Beverly Moy et al.
ONCOLOGIST (2006)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors
TPJ Garrett et al.
MOLECULAR CELL (2003)
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
CL Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
